Structure Therapeutics (GPCR) Research & Development (2022 - 2026)

Structure Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $66.5 million for Q1 2026.

• On a quarterly basis, Research & Development rose 55.15% year-over-year to $66.5 million in Q1 2026; TTM through Mar 2026 was $248.9 million, a 89.99% increase from a year earlier, with the FY2025 full-year figure at $225.3 million, up 107.01% from the prior year.
• Research & Development slipped to $66.5 million in Q1 2026 per GPCR's latest filing, from $68.7 million in the prior quarter.
• Across five years, Research & Development topped out at $68.7 million in Q4 2025 and bottomed at $8.4 million in Q4 2022.
• The 5-year median for Research & Development is $20.7 million (2024), against an average of $29.8 million.
• Across the five-year window, Research & Development grew 13.6% in 2024 and jumped 148.12% in 2025, its largest moves.
• Year by year, Research & Development stood at $8.4 million in 2022, then soared by 139.74% to $20.0 million in 2023, then jumped by 67.08% to $33.5 million in 2024, then surged by 105.12% to $68.7 million in 2025, then fell by 3.18% to $66.5 million in 2026.
• Per Business Quant, the three latest GPCR Research & Development figures stand at $66.5 million (Q1 2026), $68.7 million (Q4 2025), and $59.0 million (Q3 2025).